Five Prime and bluebird bio team up to develop new CART therapies
Five Prime Therapeutics Inc. granted bluebird bio Inc. exclusive rights to antibodies against an undisclosed target, which bluebird will develop into chimeric antigen receptor T-cell (CART) therapies for solid and blood cancers.
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.